Airiver Pulmonary Drug Coated Balloon

About Airiver Medical

Airiver Medical is a private, clinical-stage medical device company pioneering a drug-coated balloon platform for respiratory conditions. The company has secured two FDA Investigational Device Exemption (IDE) approvals in 2025 for pivotal studies in chronic rhinosinusitis and benign central airway stenosis, marking a significant step toward commercialization. With a seasoned leadership team from major medtech firms, Airiver is positioned to address large, underserved markets where current treatments often require repeated interventions. The company is currently pre-revenue as it advances its pivotal clinical programs.

Therapeutic Areas